Here, we have shown the effect of clinically used EGFR-targeted inhibitors (gefitinib and lapatinib) on the EGFR homodimerization kinetics in a basal-like breast cancer cell line, HCC1954. This evidence concerns the gene EGFR and breast carcinoma.